lovastatin has been researched along with Carcinoma, Non-Small Cell Lung in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Aksoy, HN; Ceylan, C | 1 |
| Chen, GY; Gao, YN; Hong, X; Teng, Y; Wang, M; Yang, F; Ye, LG; Zhang, X | 1 |
| Chang, VH; Chen, CC; Jiang, X; Lin, HY; Liu, YR; Wang, J; Yang, SH; Yen, Y; Zhang, K | 1 |
| Han, JY; Jung, JI; Kim, JY; Park, IH | 1 |
| Ahn, CM; Chang, J; Chang, YS; Jeon, JH; Kim, HJ; Kim, SK | 1 |
| Bradbury, PA; Dimitroulakos, J; Ding, K; Goss, G; Le Francois, BG; Zhao, TT | 1 |
| Dimitroulakos, J; Goss, G; Hanson, JE; Lagarde, AE; Lorimer, IA; Mantha, AJ | 1 |
7 other study(ies) available for lovastatin and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Comparison of the Effects of Statins on A549 Nonsmall-Cell Lung Cancer Cell Line Lipids Using Fourier Transform Infrared Spectroscopy: Rosuvastatin Stands Out.
Topics: A549 Cells; Atorvastatin; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipids; Lovastatin; Lung Neoplasms; Pravastatin; Rosuvastatin Calcium; Simvastatin; Spectroscopy, Fourier Transform Infrared | 2021 |
MCM2 is a therapeutic target of lovastatin in human non-small cell lung carcinomas.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase Inhibitor p21; G1 Phase Cell Cycle Checkpoints; Humans; Lovastatin; Lung Neoplasms; MAP Kinase Signaling System; Minichromosome Maintenance Complex Component 2; Retinoblastoma Protein; Tumor Suppressor Protein p53 | 2015 |
Lovastatin overcomes gefitinib resistance through TNF-α signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Lung Neoplasms; Male; Mice; Mice, Inbred ICR; Protein Serine-Threonine Kinases; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2015 |
Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lovastatin; Lung Neoplasms; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Signal Transduction | 2010 |
Lipid raft modulation inhibits NSCLC cell migration through delocalization of the focal adhesion complex.
Topics: beta-Cyclodextrins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cholesterol; Epidermal Growth Factor; ErbB Receptors; Focal Adhesion Kinase 1; Focal Adhesions; Humans; Lovastatin; Membrane Microdomains; Oncogene Protein pp60(v-src); Phosphorylation; Protein Stability; Protein Transport; Pseudopodia; Receptor Aggregation | 2010 |
Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins.
Topics: Amides; Animals; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cytoskeleton; Dimerization; Drug Interactions; Enzyme Activation; ErbB Receptors; Head and Neck Neoplasms; Humans; Lovastatin; Lung Neoplasms; Mice; NIH 3T3 Cells; Polyisoprenyl Phosphates; Proto-Oncogene Proteins c-akt; Pyridines; rho-Associated Kinases; Signal Transduction | 2010 |
Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Binding Sites; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colonic Neoplasms; Drug Synergism; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lovastatin; Lung Neoplasms; Mevalonic Acid; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2005 |